Remedy

 

(57) Abstract:

The invention to the field of pharmacology, and relates to a therapeutic agent. The invention lies in the fact that the product contains potassium hydroxide and an inert filler. The invention provides the ability to easily penetrate into the inner tissues of the body, to raise him to be the concentration of negatively charged ions, to cause the dissolution of salt deposits.

The invention relates to the field of pharmacology and can be used for treatment of many diseases.

Among therapeutic products containing inorganic compounds, there are drugs, pharmacological active substances which are metal hydroxide such as magnesium hydroxide (see U.S. patent, 4042685, 1977).

Known to use aqueous solutions of sodium hydroxide at low concentrations (see PCT, Z. 80/00788, class a 61 K 33/00, 1980 - prototype). A disadvantage of the known technical solution is limited in scope and lack of effectiveness of therapeutic action.

Technical solution to the problem is to increase the effectiveness of remedial actions.

The task is achieved by the fact that in a medical facility, including as the potassium, which is used with an inert filler, in the following ratio, wt.%:

Potassium hydroxide is 0.05-5,00

Filler - Rest

The novelty of the claimed proposal due to the fact that the use of potassium hydroxide broadens the scope and increases the effectiveness of therapeutic action because of the ability of potassium hydroxide is easy to penetrate into the inner tissues of the body, to raise him as the concentration of negatively charged ions, to cause the dissolution of salt deposits, to have a warming effect, to compensate for potassium deficiency that occurs in many diseases.

The proposed remedy in the form of an ointment, gel, emulsion and aqueous solution can be used for treatment of joints, arthritis, sciatica, degenerative disc disease, muscle cramps, urticaria, toothache, neuralgia, effects of insect bites, burns, heartburn and as a General tonic drug.

According to the patent and medical literature not found a similar proposal, which provides a basis for judging inventive step of the claimed proposal.

Since in the present proposal as an active ingredient is used on izlagaemogo remedies and mass of its application, that meets the eligibility criterion of "industrial application".

Remedy depending on the filler may be made in the form of an ointment, gel, emulsion and aqueous solution. The tool has no smell, the period of storage in a dry dark place at room temperature for at least one year. The drug is well combined with other methods and means of treatment. In therapeutic doses is not toxic. The factors responsible for obtaining remedies given property, is a new ingredient and the percentage of ingredients.

Because the main ingredient is potassium hydroxide, in the following examples it is taken on 100 g of the drug in the following quantities: 0,01; 0,05; 2,5; 5,00; 5,1 ,

Example 1. To inert filler, such as lanolin in the amount of 100 grams, add potassium hydroxide 0.01 g and mix thoroughly. The resulting preparation is an ointment. Due to the insufficient amount of potassium hydroxide, the product does not ensure the effectiveness of the treatment.

Example 2. To 100 g of filler added 0.05 g of potassium hydroxide. The resulting preparation is an ointment. The amount of potassium hydroxide enough for the drug began to provide medical destilated a pronounced therapeutic effect.

Example 4. The potassium hydroxide in the amount of 5.00 g is added to the filler in a quantity of 100 g of the finished product has the same trappings as the preparations in examples 1, 2, 3. Remedy also has a pronounced therapeutic effect.

Example 5. To add filler to 5.1 g of potassium hydroxide. With the high number of potassium hydroxide preparation is burning.

Received therapeutic tool used by application to the skin (to relieve allergic skin rash, effects of insect bites, burns and other), teeth cleaning (to remove and prevent the formation of Tartar), ingestion (with heartburn stomach and General malaise).

A therapeutic agent, comprising as a pharmaceutically active ingredient hydroxide metals, characterized in that the use of potassium hydroxide with an inert filler in the following ratio, wt. %:

Potassium hydroxide is 0.05-5,00

Filler - The Rest

 

Same patents:

The invention relates to new biologically active arylamides N-(3'-harbutt-2'-yl)Anthranilic acid of formula (1), where R is 2-CH3, 3-CH3that have anti-inflammatory activity and due to this can be used as the basis of new drugs

The invention relates to preparations of nimesulide for local use based gel systems

The invention relates to new derivatives of 2-renominate General formula (I), where R1and R2represent hydrogen, C1-C6-alkyl, deformity, trifluoromethyl, C3-C6-cycloalkyl, saturated 5-membered heterocycle containing one oxygen atom, indanyl, 6,7-dihydro-5H-cyclopentadienyl or1-C6-alkyl, substituted phenyl, indayla or3-C6-cycloalkyl, R3is hydrogen, R4represents hydrogen, halogen, C1-C6-alkyl, trifluoromethyl, or R4represents a radical of the formula-O-R7where R7is hydrogen, R5represents hydrogen or R4and R5taken together may form a bivalent radical of formula-CH2-CH2-O-CH2-CH2-, R6represents hydrogen or C1-C6-alkyl, -a-b - represents a bivalent radical of the formula- (CR10= CR11or СНR10-СНR11where each R10and R11independently represents hydrogen or C1-C6-alkyl, L represents hydrogen, C1-C6-alkyl, C1-C6-allyloxycarbonyl,1-C6-alkyl, substituted by one or two penilai

The invention relates to solutions for surgical irrigation and methods of use thereof, in particular to anti-inflammatory, analgesic and anticonvulsant solutions

The invention relates to medicine and to the use of at least one peptide containing the C-end of the Tripeptide Lysine-Proline-Valine, in which a Proline residue is in the form of programalso optical isomer for the local treatment of inflammation
The invention relates to pharmaceutical industry and veterinary

The invention relates to cosmetology

The invention relates to the processing of larch wood with getting bioflavonoids, specifically dihydroquercetin (DQC), which finds application in medicine, food industry

The invention relates to new phenanthridine derivative of the General formula I and II and their salts, where R1represents an aromatic carbocyclic residue, which is derived from benzene or naphthalene, or represents a heterocyclic residue, which is derived from furan, thiophene or pyridine, and R1may have one or more substituents, and these substituents selected from monoamino, alkylamino, dialkylamino-, alkyl-, alkoxy-, alkylene and galactography, a R2and R3that may be the same or raznie, represent a hydrogen atom, CNS residue, accelerometry residue, a halogen atom or a nitro-group

The invention relates to medicine and can be used to treat a variety of rhinitis: allergic, polynosic, year-round
The invention relates to medicine, namely to addiction, and can be used in the treatment of alcoholism and addiction, and rehabilitation therapy body functions

The invention relates to the field of veterinary medicine
The invention relates to medicine, in particular to urology
The invention relates to medicine, in particular to surgery, and can be used when carrying out reconstructive operations
The invention relates to medicine and can be used for the treatment of trophic ulcers of lower extremities in people with advanced forms of the disease

The invention relates to medicine, namely to surgery, and can be used for the treatment of peritonitis
The invention relates to medicine, in particular for experimental medicine, and can be used for transplantation of the skin in mammals

The invention relates to medicine and relates to a means for relief of alcohol withdrawal syndrome

The invention relates to medicine and can be used to adjust parameters of the system of hemostasis

The invention relates to medicine, in particular infectious diseases, and can be used for the treatment of acute viral hepatitis with cholestatic component

The invention relates to medicine and relates to oral pharmaceutical dosage forms containing sensitive to acid proton pump inhibitor and one or more antacid substances or alginate in a fixed structure in which the proton pump inhibitor is protected by a layer Intercollege coating and optionally a separating layer between proton pump inhibitor and intersolubility coating, the fixed part has the form of a multilayer tablets, sachets or complex tablet dosage forms
Up!